1995 Fiscal Year Final Research Report Summary
Dose-up of chemotherapy regimen with a support of autologous bone marrow transplantation.
| Project/Area Number |
05671401
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
SHINOZUKA Takao Tokai University, School of Medicine, Associate Professor, 医学部, 助教授 (30110901)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OSAMURA Yoshiyuki Tokai University, School of Medicine, Professor, 医学部, 教授 (10100992)
MIYAMOT Tsuyosi Tokai University, School of Medicine, Instructor, 医学部, 助手 (60209947)
MURAKAMI Masaru Tokai University, School of Medicine, Assistant Professor, 医学部, 講師 (00190893)
|
|---|
| Project Period (FY) |
1993 – 1995
|
| Keywords | Overian Cancer / High dose chemotherapy / Autologous bone marrow transplantation |
|---|
| Research Abstract |
High dose chemoterapy with support of autologous bone marrow transplantation was performed in patients with advanced epithelial ovarian cancer for improvement of long term survivals. Since September, 1984,63 patients (stage II 10, III 35, and IV 18 patients) received the chemotherapy after primary debulking surgery. Regimen of the chemotherapy per course were combination of cyclophosphamide 1600-2400 mg/m^2+doxorubicin 80-100 mg/m^2+ cisplatin 100-150 mg/m^2 in 44 patients, and cyclophosphamide 3000 mg/m^2+ carboplatin 900-1500 mg/m^2 in 19 patients.
Five-year survival rates of the 63 patients by Kaplan-Meier method were 80.0% in stage II,61.8% in stage III,and 31.8% in stage IV patients.In stage III patients with adjuvant setting by CAP regimen showed better prognosis (5-year survival 87.5%) than therapeutic setting (5-year survival 41.7%) . In 32 patients of stage III,IV who received 2 course of high-dose CAP chemoterapy, a group (18 patients) who received 150 mg/m^2 course of cisplatin, showed better survival (5-year : 66.7%) than the other group (14 patients) of receiving under 135 mg/m^2 course of cisplatin (5year 35.7%) . Four-year survival rate of the 19 patients (stage II 3, III 10, IV 6 patients) who received cyclophosphamide + carboplatin chemotherapy was 61.4%. These results implicate that dose-up of platinum delivatives amount course, and minimalresidual disease extent are important factors for improvement of long-term survivals of advanced ovarian cancer.
|
